Coenzyme Q_10 and Congestive Heart Failure
Authors: Stephen T. Sinatra
Journal: Annals of Internal Medicine (2000)

Letters7 November 2000Coenzyme Q10 and Congestive Heart FailureStephen T. Sinatra, MDStephen T. Sinatra, MDNew England Heart Center; Manchester, CT 06040 (Sinatra)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-9-200011070-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Khatta and colleagues' study (1) was too short in duration and the dosage of coenzyme Q10 too low for patients with class III and class IV congestive heart failure. Earlier research indicated that therapeutic blood levels of coenzyme Q10 should be at least 2.5 µg/mL to elicit a biosensitive result (2). In Khatta and colleagues' study, 19 of 22 patients had blood levels lower than this minimal amount. In another investigation, optimum improvement in myocardial function occurred with an average blood level of 2.9 µg/mL (3). When higher blood levels are obtained (>3.5 µg/mL), subjective or objective ...References1. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, Robinson SW, et al . The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636-40. LinkGoogle Scholar2. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr. 1988;66:583-90. CrossrefMedlineGoogle Scholar3. Langsjoen PH, Langsjoen AM. CoEnzyme Q10 in cardiovascular disease with emphasis on heart failure and myocardial ischemia. Asia-Pacific Heart Journal. 1998;7:160-8. CrossrefGoogle Scholar4. Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol. 1987;9:734-42. CrossrefMedlineGoogle Scholar5. Kishi T, Kishi H, Folkers K. Inhibition of cardiac CoQ10-enzymes by clinically used drugs and possible prevention. In: Folkers K, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. Vol 1. Amsterdam: Elsevier/North-Holland Biomedical Pr; 1977:47-62. Google Scholar Author, Article, and Disclosure InformationAffiliations: New England Heart Center; Manchester, CT 06040 (Sinatra) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Effect of Coenzyme Q10 in Patients with Congestive Heart Failure Meenakshi Khatta , Barbara S. Alexander , Cathy M. Krichten , Michael L. Fisher , Ronald Freudenberger , Shawn W. Robinson , and Stephen S. Gottlieb Coenzyme Q10 and Congestive Heart Failure Stephen S. Gottlieb , Meenakshi Khatta , and Michael L. Fisher Metrics Cited ByCoenzyme Q10 for heart failureCoenzyme Q10Chronic Fatigue SyndromeCoenzyme Q10 for heart failureHeart Mitochondrial ROS and Oxidative StressCoenzyme Q10Micronutrient DeficienciesCongestive Heart Failure and Cardiomyopathy 7 November 2000Volume 133, Issue 9Page: 745KeywordsAdenosine triphosphateAngiotensin converting enzyme inhibitorAttentionBiopsyBloodCoenzymesEnzymesHeart failureLongitudinal studiesReasoning ePublished: 7 November 2000 Issue Published: 7 November 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...